sk&f-38393 has been researched along with Parkinson Disease in 28 studies
2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine: A selective D1 dopamine receptor agonist used primarily as a research tool.
1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diol : A benzazepine that is 2,3,4,5-tetrahydro-3-benzazepine bearing a phenyl substituent at position 1 and two hydroxy substituents at positions 7 and 8.
SKF 38393 : A racemate comprising equimolar amounts of (R)- and (S)-SKF 38393
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| " All rats separately underwent dose-response behavior testing for SKF38393 (0, 0." | 1.62 | Effects of intrastriatal injection of the dopamine receptor agonist SKF38393 and quinpirole on locomotor behavior in hemiparkinsonism rats. ( Chen, D; Guo, M; He, F; Jia, Q; Li, M; Li, Y; Sun, S; Sun, Y; Wang, M; Wang, X; Xiang, T; Yao, X; Zhang, X, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (25.00) | 18.7374 |
| 1990's | 9 (32.14) | 18.2507 |
| 2000's | 9 (32.14) | 29.6817 |
| 2010's | 2 (7.14) | 24.3611 |
| 2020's | 1 (3.57) | 2.80 |
| Authors | Studies |
|---|---|
| Guo, M | 1 |
| Xiang, T | 1 |
| Li, M | 1 |
| Sun, Y | 1 |
| Sun, S | 1 |
| Chen, D | 1 |
| Jia, Q | 1 |
| Li, Y | 1 |
| Yao, X | 1 |
| Wang, X | 1 |
| Zhang, X | 1 |
| He, F | 1 |
| Wang, M | 1 |
| Frau, L | 1 |
| Morelli, M | 2 |
| Simola, N | 1 |
| Fisone, G | 1 |
| Vorobyov, VV | 1 |
| Schibaev, NV | 1 |
| Carta, AR | 1 |
| Yoshimura, N | 1 |
| Kuno, S | 1 |
| Chancellor, MB | 1 |
| De Groat, WC | 1 |
| Seki, S | 1 |
| Kovoor, A | 1 |
| Seyffarth, P | 1 |
| Ebert, J | 1 |
| Barghshoon, S | 1 |
| Chen, CK | 1 |
| Schwarz, S | 1 |
| Axelrod, JD | 1 |
| Cheyette, BN | 1 |
| Simon, MI | 1 |
| Lester, HA | 1 |
| Schwarz, J | 1 |
| Kachroo, A | 1 |
| Orlando, LR | 1 |
| Grandy, DK | 1 |
| Chen, JF | 1 |
| Young, AB | 1 |
| Schwarzschild, MA | 1 |
| Zhang, H | 1 |
| Ma, L | 1 |
| Wang, F | 1 |
| Chen, J | 1 |
| Zhen, X | 1 |
| Gershanik, O | 1 |
| Heikkila, RE | 2 |
| Duvoisin, RC | 1 |
| Fornaguera, J | 1 |
| Huston, JP | 1 |
| Carey, RJ | 1 |
| Schwarting, RK | 1 |
| Olsson, M | 1 |
| Nikkhah, G | 2 |
| Bentlage, C | 2 |
| Björklund, A | 2 |
| Silverman, PB | 1 |
| Watts, VJ | 1 |
| Lawler, CP | 1 |
| Gilmore, JH | 1 |
| Southerland, SB | 1 |
| Nichols, DE | 1 |
| Mailman, RB | 1 |
| Boldry, RC | 1 |
| Chase, TN | 5 |
| Engber, TM | 1 |
| Cunningham, MG | 1 |
| Brooks, S | 1 |
| Kaur, S | 1 |
| Starr, BS | 1 |
| Starr, MS | 1 |
| Rodríguez-Puertas, R | 1 |
| Herrera-Marschitz, M | 1 |
| Koistinaho, J | 1 |
| Hökfelt, T | 1 |
| Popoli, P | 1 |
| Reggio, R | 1 |
| Pèzzola, A | 1 |
| Hayakawa, T | 1 |
| Chang, MC | 1 |
| Rapoport, SI | 1 |
| Appel, NM | 1 |
| Zhao, Y | 1 |
| Kerscher, N | 1 |
| Eysel, U | 1 |
| Funke, K | 1 |
| Pendleton, RG | 1 |
| Parvez, F | 1 |
| Sayed, M | 1 |
| Hillman, R | 1 |
| Paul, ML | 1 |
| Graybiel, AM | 1 |
| David, JC | 1 |
| Robertson, HA | 1 |
| Braun, A | 2 |
| Fabbrini, G | 2 |
| Mouradian, MM | 2 |
| Serrati, C | 1 |
| Barone, P | 3 |
| Braun, AR | 1 |
| Tamminga, CA | 1 |
| Sonsalla, PK | 1 |
| Manzino, L | 1 |
| Jenner, P | 1 |
| Marsden, CD | 1 |
| Bankiewicz, KS | 1 |
| Corsini, GU | 1 |
| Kopin, IJ | 1 |
1 review available for sk&f-38393 and Parkinson Disease
| Article | Year |
|---|---|
The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzaze | 1986 |
1 trial available for sk&f-38393 and Parkinson Disease
| Article | Year |
|---|---|
Selective D-1 dopamine receptor agonist treatment of Parkinson's disease.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Aged; Benzazepines; Double-Blind Method; | 1987 |
26 other studies available for sk&f-38393 and Parkinson Disease
| Article | Year |
|---|---|
Effects of intrastriatal injection of the dopamine receptor agonist SKF38393 and quinpirole on locomotor behavior in hemiparkinsonism rats.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Corpus Striatum; Disease Models | 2021 |
Performance of movement in hemiparkinsonian rats influences the modifications induced by dopamine agonists in striatal efferent dynorphinergic neurons.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Adrenergic Agents; Analysis of Variance; | 2013 |
Monitoring dyskinesia with Zif.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Antiparkinson Agents; Biomarker | 2010 |
EEG modifications in the cortex and striatum after dopaminergic priming in the 6-hydroxydopamine rat model of Parkinson's disease.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Adrenergic Agents; Animals; Apomorphine; | 2003 |
Dopaminergic mechanisms underlying bladder hyperactivity in rats with a unilateral 6-hydroxydopamine (6-OHDA) lesion of the nigrostriatal pathway.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Benzopyrans; Disease Models, An | 2003 |
D2 dopamine receptors colocalize regulator of G-protein signaling 9-2 (RGS9-2) via the RGS9 DEP domain, and RGS9 knock-out mice develop dyskinesias associated with dopamine pathways.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Antiparkinson Agents; Antipsych | 2005 |
Interactions between metabotropic glutamate 5 and adenosine A2A receptors in normal and parkinsonian mice.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Analysis of Variance; Animals; Animals, | 2005 |
Chronic SKF83959 induced less severe dyskinesia and attenuated L-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Analysis of Variance; Animals; Disease M | 2007 |
Behavioral correlations of dopamine receptor activation.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Benzazepines; Disease Models, A | 1983 |
Stimulation of D1- or D2-receptors in drug-naive rats with different degrees of unilateral nigro-striatal dopamine lesions.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Behavior, Animal; Dopamine; Erg | 1995 |
Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Analysis of Variance; Animals; Apomorphi | 1995 |
On-off effects of dopamine receptor agonists in the hemi-parkinsonian rat.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Bromocriptine; Cocaine; Dopamin | 1993 |
Dopamine D1 receptors: efficacy of full (dihydrexidine) vs. partial (SKF38393) agonists in primates vs. rodents.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Adenylyl Cyclases; Animals; Dopamine Age | 1993 |
Influence of previous exposure to levodopa on the interaction between dizocilpine and dopamine D1 and D2 agonists in rats with 6-hydroxydopamine-induced lesions.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Behavior, Animal; Brain Disease | 1993 |
Intranigral fetal dopamine grafts induce behavioral compensation in the rat Parkinson model.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Amphetamine; Animals; Behavior, Animal; | 1994 |
Motor actions of eliprodil in the normal and monoamine-depleted mouse: a role in the treatment of Parkinson's disease?
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Behavior, Animal; Biogenic Mono | 1996 |
Dopamine D1 receptor modulation of glutamate receptor messenger RNA levels in the neocortex and neostriatum of unilaterally 6-hydroxydopamine-lesioned rats.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Corpus Striatum; Dopamine; Dopa | 1999 |
Effects of SCH 58261, an adenosine A(2A) receptor antagonist, on quinpirole-induced turning in 6-hydroxydopamine-lesioned rats. Lack of tolerance after chronic caffeine intake.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Behavior, Animal; Caffeine; Cen | 2000 |
Selective dopamine receptor stimulation differentially affects [3H]arachidonic acid incorporation, a surrogate marker for phospholipase A2-mediated neurotransmitter signal transduction, in a rodent model of Parkinson's disease.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Arachidonic Acid; Biomarkers; D | 2001 |
Changes of contrast gain in cat dorsal lateral geniculate nucleus by dopamine receptor agonists.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Action Potentials; Animals; Cats; Contra | 2001 |
Effects of pharmacological agents upon a transgenic model of Parkinson's disease in Drosophila melanogaster.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; alpha-Methyltyrosine; alpha-Synuclein; A | 2002 |
D1-like and D2-like dopamine receptors synergistically activate rotation and c-fos expression in the dopamine-depleted striatum in a rat model of Parkinson's disease.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Amino Acid Sequence; Animals; Behavior, | 1992 |
D-1/D-2 dopamine receptor interactions in the regulation of extrapyramidal motor function: studies in animal models and parkinsonian patients.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Benzazepines; Ergolines; Humans | 1986 |
Dopamine D-1 receptor agonist stimulation of prolactin secretion in man.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Benzazepines; Dyskinesia, Drug-Induced; | 1988 |
Interactions of D1 and D2 dopamine receptors on the ipsilateral vs. contralateral side in rats with unilateral lesions of the dopaminergic nigrostriatal pathway.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Basal Ganglia; Benzazepines; Co | 1988 |
Dopaminergic mechanisms in hemiparkinsonian monkeys.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Benzazepines; Biomechanical Phe | 1987 |